60. Aplastic anemia Clinical trials / Disease details
Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100051874 | 2021-10-01 | 2021-10-08 | Efficacy and safety of ruxolitinib in preventing aGVHD after haplotype bone marrow transplantation in severe aplastic anemia | Efficacy and safety of ruxolitinib in preventing aGVHD after haplotype bone marrow transplantation in severe aplastic anemia | Severe aplastic anemia | experimental group:ruxolitinib; | The Second Affiliated Hospital of Dalian Medical University | NULL | Recruiting | 1 | 60 | Both | experimental group:20; | N/A | China |